The Evolution & Medicine Review

One of the areas of biomedical research currently drawing a great deal of attention is regenerative medicine. This approach depends on the use of human pluripotent stem cells (hPS) or induced human pluripotent stem cells (hiPS). There are many medically relevant uses envisioned for these cells. All of these potentially exciting applications ultimately require growing stem cells in tissue culture. In a new paper in Nature from Kevin Eggan’s lab (1), Merkle et al. demonstrate that some hPS cell lines being expanded in culture incur mutations in the TP53 gene (on the short arm of human chromosome 17) that are also found in and likely contribute to the causation of cancer.

Eggan and colleagues obtained and performed whole-exome sequencing on 114 human embryonic stem (hES) cell lines from the National Institutes of Health and 26 independent lines that had been prepared for clinical applications. Previous studies had documented copy number variants in hES cells maintained in culture (2-4). These variants in chromosome structure were in some cases found to favor the proliferation of hES cells containing these variants over the cells not containing them.

So the authors of the present study asked whether there were simpler genetic variations, such as mis-sense mutations, that also arise in culture hES cells and confer selective advantages in tissue culture. In this effort, they selected hES cell lines with 3-37 prior passages (average of 18 passages). Before banking and sequencing the exomes of the hES cell lines they chose, they passaged the lines for an average of between 2 and 3 times (range 2-6).

The authors took steps to avoid identifying routine polymorphisms as culture-acquired mutations. First, they searched for variants that occurred in only 1 or 2 cell lines. Second, they looked for variants that were present in the exomes of <0.01% of normal individuals sampled by the Exome Aggregation Consortium (ExAC Database). They also employed additional statistical tests to prevent identification of variants that were unlikely to be acquired in culture. Ultimately, they identified 263 mosaic variants, 28 of which were predicted to interfere with protein function. There was only a single gene affected by more than one such mutation:TP53. The gene product, p53, encoded byTP53 serves as a regulator of DNA damage and apoptosis and is regarded as a tumor suppressor gene. TP53 is among the most common genes mutated in human cancers (5) and is found to have a mutation in as many as 50% of all tumors (6).

The six TP53 mutations identified in five different hES cell lines affected the four amino acid residues in p53 that are most frequently mutated in human cancers. All four of these amino acids are located in the DNA-binding domain of p53 and substitutions at these positions are found in cancer and are observed to act as dominant negative mutations, i.e. they subvert the function of p53 that is un-mutated. Of comparable interest, germ-line mutations at these same residues in p53 cause an autosomal dominant disease, Li-Fraumeni syndrome, that predisposes to cancers of many different tissues with a lifetime risk approaching 100% (7). The fact that both somatic and germ-line mutations in these residues of p53 can act dominantly is highly compatible with the notion that these mutations, occurring on only one allele of the pair in a diploid cell, could confer highly advantageous phenotypes in cells growing in tissue culture.

The authors developed an assay to permit them to assess the frequency of alleles involving these particular mutations in the 140 hES cell lines. Results of the assay indicated that the allele frequency ranged from 7-40% with 14-80% of the cells in culture. These findings suggest that these p53 mutations were acquired in culture. Additional experiments followed the frequency of these mutations through two or more additional passages. In three different cell lines, the frequencies of the alleles representing one of the six TP53 mutations increased during these serial passages in all but one experiment suggesting that these alleles were favored by selection under the conditions of typical cell culture. So, an unfortunate parallel exists between tumors in vivo and hES cell lines in vitro in that genetic events subverting p53 function favor the relative increase in numbers of cells bearing p53-inactivating mutations.

In an effort to explore the generality of their findings with hES cells, the authors searched for TP53 mutations in publicly available RNA sequencing data from human pluripotent stem cells (hPS) and human induced pluripotent stem cells (hiPS). They found nine more instances of eight distinct TP53 mutations, all in the DNA-binding domain. Another finding of importance was that in addition to mis-sense mutations, loss-of-heterozygosity (LOH) for TP53 due to deletions could also be found in some cell lines.

Some years ago when I devoted time to delineating the flaws and deficiencies of “Intelligent Design,” it occurred to me that the problem relating to evolution was not whether it occurred but that you cannot escape it. Having done a substantial amount of tissue culture in the early portion of my career, and employed a specific technique to select for spontaneous hybridoma variants for one project, I have long counseled colleagues and trainees that cells in tissue culture are likely to evolve over multiple passages and not necessarily in a desired direction. Eggan and colleagues have now added important new information demonstrating that these notions also apply to hES, hPS, and hiPS cells.

The relevance of the present findings for clinical medicine is substantial. These various types of stem cell lines are being developed for use both in creating in vitro disease models to facilitate both basic investigation of disease mechanisms and screening of drugs (either of which could be patient-specific), and in vivo therapy. With respect to the latter application, there is much hope that pluripotent stem cells can be used both to restore function to damaged organs or tissues and ultimately to create immunogenetically compatible organs to replace failing organs.

As the authors conclude, their evidence and evidence from previous studies suggests that in vitro amplification of pluripotent stem cells may need to be modified and refined to minimize the extent to which potentially cancer-causing mutations are favored. Furthermore, it will probably be necessary to monitor stem cell lines prior to clinical use for mutations that could, if not detected, lead to iatrogenic malignancy. Even in vitro use of hPS or hiPS cells for exploration of pathogenetic mechanisms or drug screening could be problematic if the cancer-related mutations, or other genetic variations acquired in culture, influenced the cells in ways that made the findings unrepresentative of the same cells without such mutations.



  1. Merkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, Kashin S,

Mekhoubad S, Ilic D, Charlton M, Saphier G, Handsaker RE, Genovese G, Bar S,

Benvenisty N, McCarroll SA, Eggan K. Human pluripotent stem cells recurrently

acquire and expand dominant negative P53 mutations. Nature. 2017 Apr 26. doi:

10.1038/nature22312. [Epub ahead of print] PubMed PMID: 28445466.


  1. International Stem Cell Initiative., Adewumi O, … Zhang W. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol. 2007 Jul;25(7):803-16. Epub 2007 Jun 17. PubMed PMID: 17572666.


  1. International Stem Cell Initiative., Amps K, … Zhou Q. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011 Nov 27;29(12):1132-44. doi: 10.1038/nbt.2051. PubMed PMID: 22119741; PubMed Central PMCID: PMC3454460.
  2. Baker D, Hirst AJ, Gokhale PJ, Juarez MA, Williams S, Wheeler M, Bean K, Allison TF, Moore HD, Andrews PW, Barbaric I. Detecting Genetic Mosaicism in Cultures of Human Pluripotent Stem Cells. Stem Cell Reports. 2016 Nov 8;7(5):998-1012. doi: 10.1016/j.stemcr.2016.10.003. PubMed PMID: 27829140; PubMed Central PMCID: PMC5106530.


  1. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins,

consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010

Jan;2(1):a001008. doi: 10.1101/cshperspect.a001008. Review. PubMed PMID:

20182602; PubMed Central PMCID: PMC2827900.


  1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000 Nov 16;408(6810):307-10. PubMed PMID: 11099028.


7. Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011 Apr;2(4):475-84. doi:

10.1177/1947601911413466. PubMed PMID: 21779515; PubMed Central PMCID:



Tags: human embryonic stem cells, human pluripotent stem cells, human induced pluripotent stem cells, cell line, tissue culture, cellular proliferation, selection, in vitro evolution, whole-exome sequencing, copy number variant, missense mutation, loss of heterozygosity, TP53 gene, p53, DNA-binding domain, cancer, disease pathogenesis, drug screening, organ transplantation